Perspective Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $375.9M
- Price
- $3.30
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.80%
- Volume
- 1.1M
About
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Quick stats
Shares outstanding113.9M
Computed float94.7M
Float / shares83.1%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000728387
AI Summary
AI-generated1/36
standardbullishearnings
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
Perspective Therapeutics reported $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026, extending its runway into late 2027, while its Q2 net loss per share improved to $0.22 from $0.29 in the prior year.
The company is advancing its lead asset VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, targeting regulatory alignment and site activation around year-end 2026, with updated data slated for presentation at ESMO.
Corporate updates include the appointment of Paul Lyne, Ph.D. as Chief Science Officer and the progression of a new manufacturing facility in Chicago, expected to complete construction in early 2027.